Tel Aviv Stock Exchange (TASE) has approved today the new listing of MannKind Corporation‘s common shares beginning on October 28, 2015 under the ticker symbol MNKD.
Based on the current market capitalization, MannKind’s shares are anticipated to be included in five TASE equity indexes: TASE’s TA-75, TA-100, TA-BlueTech, TA-Tech-Elite and TA-Biomed.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
“The new listing also offers an opportunity to expand and diversify our shareholder base by increasing our exposure and improving our accessibility to Israeli investors, ” said Hakan Edstrom, President and CEO of MannKind. “This listing is also an extension of the long-standing relationship between our Executive Chairman, Alfred Mann, and the Israeli biotechnology industry, including the Alfred Mann Institute at the Technion (Israel Institute of Technology).”
TASE CEO, Yossi Beinart pointed on the MannKind’s long and strong relations with the Israeli Biomed Sector, via the founder and executive chairman Mr. Alfred E. Mann, one of pioneers of the Biomed sector in the U.S., “who has supported developing and commercializing Israeli technologies for many years.”
“We are proud that a company with a market value of more than a billion US dollars chose to join 50 dually-listed companies, as well as the TASE leading indices.”, Mr. Beinart added, “joining TASE entitles MannKind to significant benefits, including added exposure among Israeli investors, extension of the trading duration, investment by Exchange Traded Product vendors and easy access to institutional and retail investors.”
